### Contents

Request for Applications Neurodegeneration Challenge Network CZI Ben Barres Early Career Acceleration Awards ................................................................. 2

Request for Applications Neurodegeneration Challenge Network CZI Collaborative Science Awards .................................................................................................................. 5

Michigan Health Endowment Fund 2018 Behavioral Health Initiative ........................................ 7

Request for Letters of Intent The Honorable Tina Brozman Foundation for Ovarian Cancer Research Individual Investigator Awards 2019-2020 ........................................................................ 8

Chordoma Foundation and The Mark Foundation: Therapeutic Innovation Award ...................... 8

Cystinosis Research Foundation Spring 2018 Call for Research Proposals and Postdoctoral Research Fellowships .......................................................................................... 9

Request for Proposal: Colorectal Cancer Screening Links of Care Web-Based Training ...... 10

Request for Proposals on Propionic Acidemia ............................................................................ 11

National Psoriasis Foundation Request for Proposals: Bridge Grants ........................................ 12

Request for Proposals: Brain Aneurysm Research Grant ......................................................... 12

Children's Cardiomyopathy Foundation Research Grant Program ........................................... 13

Tell Every Amazing Lady About Ovarian Cancer Louisa M. McGregor Ovarian Cancer Foundation 2018 Medical Research Program ................................................................. 14

Request for Proposals: 2018 Global ASPIRE Transthyretin (TTR) Amyloidosis Competitive Research Grant Awards for Junior Investigators .......................................................... 14

National Cancer Center Post-Doctoral Fellowships .................................................................. 16

Albert and Mary Lasker Foundation 2018 Essay Contest ........................................................... 17

Biosimilars - Immunology Investigator Studies Program ........................................................ 17

Diabetes and Metabolism Investigator Studies Program ........................................................... 18

Antimicrobial Stewardship Investigator Studies Program ......................................................... 19

Antibacterial Investigator Studies Program ................................................................................. 20

Antibacterial Investigator Studies Program—Clostridium difficile ........................................... 22

CMV Investigator Studies Program ............................................................................................. 23

Antifungal Investigator Studies Program ..................................................................................... 24

HIV Investigator Studies Program ............................................................................................. 25

Alzheimer's Disease Investigator Studies Program ..................................................................... 26

Insomnia Investigator Studies Program ...................................................................................... 27

Oncology Translational Studies Program (OTSP) .................................................................... 28
Please note that a faculty member’s research administrator will serve as the liaison on all aspects of the internal application process. If you are unsure of whom to talk to, your department contact can be found at the following link. If you pursue any grant opportunity featured in this report, please contact your research administrator first to formulate a submission plan and timeline.

The UMHS Corporate and Foundation Relations team can assist in this process, including providing direct communication with the funding entity to obtain guidance on project appeal/applicability to the funder, provide examples of previously funded UM proposals, and answer general faculty questions.

Grantor: Chan Zuckerberg Initiative
Grant Opportunity: Career Development
Keyword: Basic Science; Career Development; Chronic Diseases; Neurological Disorders; Neuromuscular Disorders; Research Grant
Award Amount: $2.5 Million
Deadline: April 17, 2018

Request for Applications Neurodegeneration Challenge Network CZI Ben Barres Early Career Acceleration Awards

http://czi-wp-blue.scivulcan.com/science/rfa
The Chan Zuckerberg Initiative invites applications to join the CZI Neurodegeneration Challenge Network, an interdisciplinary collaborative initiative to increase understanding of the fundamental biology of neurodegenerative disorders. Applications are being accepted for two funding mechanisms:

CZI Ben Barres Early Career Acceleration Awards: investigator awards for early career academic investigators, especially those who are new to the field of neurodegeneration

CZI Collaborative Science Awards: awards for small group interdisciplinary collaborations that include a physician with active clinical engagement

Opportunity: The CZI Neurodegeneration Challenge Network has three goals: (1) to make fundamental advances toward understanding neurodegeneration; (2) to bring new ideas and talent to the field of neurodegeneration; and (3) to encourage a new type of interdisciplinary collaborative research involving scientists, clinicians and engineers.

We invite applications to join the Neurodegeneration Challenge Network through two RFA mechanisms:

CZI Ben Barres Early Career Acceleration Awards: five-year investigator grants for early career academic investigators, with an emphasis on those who are new to the field of neurodegeneration. We seek to empower investigators to pursue bold ideas and to take risks within a supportive and collaborative environment. Awardees will benefit from mentorship support, as well as professional development, training and network opportunities, and practical career guidance to help them navigate this early stage of their careers.

CZI Collaborative Science Awards: three-year grants for small group interdisciplinary collaborations. At least one member of the collaboration should be a physician with active clinical engagement in an area relevant to the proposal. These grants are aimed to support innovative, bold, high risk/high impact projects at the interface of basic and disease biology. The scope of these collaborations should focus on foundational science (as opposed to translation and clinical application), aligned with clinical context.

The goal of the Neurodegeneration Challenge Network is to bring together outstanding, innovative, forward-thinking scientists from different disciplines, into a collaborative network to work together on questions related to the basic cell biological mechanisms of neurodegeneration in the context of human disease biology.

To encourage new ideas, we strongly encourage applications from researchers who are working in relevant fields outside of neurodegeneration and neuroscience (such as cell biology, immunology, metabolism, physiology, and computational biology). Previous work in neurodegeneration is not a prerequisite, as long as the proposal is able to make a strong case for potential relevance to neurodegeneration.

Scientific Scope
This is explicitly not a translational or clinical development RFA and rather is aimed at foundational and mechanistic studies. Nonetheless, successful projects should be grounded in human biology and disease pathology, and the goal is that these efforts will ultimately provide new avenues and rigorous foundations for other translational and clinical development work.

We encourage applications both from investigators who are tackling underexplored topics, as well as those addressing more well-developed mechanisms where there remain significant gaps in understanding.

Examples of potential areas within the scope of the Neurodegeneration Challenge Network include, but are not limited to:

Understanding common disease mechanisms that cut across disease and that may point to common avenues for intervention.

Probing disease mechanisms in human cells, tissues, and models; foundational studies that rigorously bridge between model systems approaches and human biology and disease pathology.

Defining the contribution of non-neuronal influences on neurodegeneration, including potential influences of the innate and adaptive immune systems, vasculature, and the gut and microbiome.

Developing improved animal models that more closely mimic human disease progression and physiology.

Explaining the relative susceptibility of different cell populations in different neurodegenerative diseases.

Testing causal hypotheses for how core cellular mechanisms such as metabolic regulation, proteostasis, RNA processing, and protein trafficking contribute to neurodegenerative diseases.

Building a foundational understanding of disease progression, risk, and the influence of aging over the lifespan, including mechanistic approaches as well as longitudinal descriptive studies.

Budget: $500K total costs per year for five years, for a total of $2.5M (including up to 15% indirect costs).

April 17, 2018: Applications due by 5 pm PT

Grantor: Chan Zuckerberg Initiative
Grant Opportunity: Research Grans
Keyword: Basic Science; Chronic Diseases; Neurological Disorders; Neuromuscular Disorders; Research Grant
Award Amount: $1.05 Million
Deadline: April 3, 2018
The Chan Zuckerberg Initiative invites applications to join the CZI Neurodegeneration Challenge Network, an interdisciplinary collaborative initiative to increase understanding of the fundamental biology of neurodegenerative disorders. Applications are being accepted for two funding mechanisms:

**CZI Ben Barres Early Career Acceleration Awards:** investigator awards for early career academic investigators, especially those who are new to the field of neurodegeneration

**CZI Collaborative Science Awards:** awards for small group interdisciplinary collaborations that include a physician with active clinical engagement

Opportunity: The CZI Neurodegeneration Challenge Network has three goals: (1) to make fundamental advances toward understanding neurodegeneration; (2) to bring new ideas and talent to the field of neurodegeneration; and (3) to encourage a new type of interdisciplinary collaborative research involving scientists, clinicians and engineers.

We invite applications to join the Neurodegeneration Challenge Network through two RFA mechanisms:

**CZI Ben Barres Early Career Acceleration Awards:** five-year investigator grants for early career academic investigators, with an emphasis on those who are new to the field of neurodegeneration. We seek to empower investigators to pursue bold ideas and to take risks within a supportive and collaborative environment. Awardees will benefit from mentorship support, as well as professional development, training and network opportunities, and practical career guidance to help them navigate this early stage of their careers.

**CZI Collaborative Science Awards:** three-year grants for small group interdisciplinary collaborations. At least one member of the collaboration should be a physician with active clinical engagement in an area relevant to the proposal. These grants are aimed to support innovative, bold, high risk/high impact projects at the interface of basic and disease biology. The scope of these collaborations should focus on foundational science (as opposed to translation and clinical application), aligned with clinical context.

The goal of the Neurodegeneration Challenge Network is to bring together outstanding, innovative, forward-thinking scientists from different disciplines, into a collaborative network to work together on questions related to the basic cell biological mechanisms of neurodegeneration in the context of human disease biology.

To encourage new ideas, we strongly encourage applications from researchers who are working in relevant fields outside of neurodegeneration and neuroscience (such as cell biology, immunology, metabolism, physiology, and computational biology). Previous work in
neurodegeneration is not a prerequisite, as long as the proposal is able to make a strong case for potential relevance to neurodegeneration.

Scientific Scope

This is explicitly not a translational or clinical development RFA and rather is aimed at foundational and mechanistic studies. Nonetheless, successful projects should be grounded in human biology and disease pathology, and the goal is that these efforts will ultimately provide new avenues and rigorous foundations for other translational and clinical development work.

We encourage applications both from investigators who are tackling underexplored topics, as well as those addressing more well-developed mechanisms where there remain significant gaps in understanding.

Examples of potential areas within the scope of the Neurodegeneration Challenge Network include, but are not limited to:

- Understanding common disease mechanisms that cut across disease and that may point to common avenues for intervention.
- Probing disease mechanisms in human cells, tissues, and models; foundational studies that rigorously bridge between model systems approaches and human biology and disease pathology.
- Defining the contribution of non-neuronal influences on neurodegeneration, including potential influences of the innate and adaptive immune systems, vasculature, and the gut and microbiome.
- Developing improved animal models that more closely mimic human disease progression and physiology.
- Explaining the relative susceptibility of different cell populations in different neurodegenerative diseases.
- Testing causal hypotheses for how core cellular mechanisms such as metabolic regulation, proteostasis, RNA processing, and protein trafficking contribute to neurodegenerative diseases.
- Building a foundational understanding of disease progression, risk, and the influence of aging over the lifespan, including mechanistic approaches as well as longitudinal descriptive studies.

Budget: $350K total costs per year for three years, for a total of $1.05M (including up to 15% indirect costs).

April 3, 2018: Letters of Intent due by 5 pm PT

Grantor: Michigan Health Endowment Fund

Grant Opportunity: Program Funding

Keyword: Psychosocial; Public Health
Award Amount: $500,000

Deadline: March 15, 2018

Michigan Health Endowment Fund 2018 Behavioral Health Initiative

http://healthendowmentfund.org/behavioral-health-grant/

The aims of the Michigan Health Endowment Fund’s 2018 Behavioral Health Initiative are to improve health outcomes and reduce overall healthcare costs by increasing access to high-quality, person-centered, and integrated mental health and substance use disorder services for Michigan residents. To achieve these improvements, the Health Fund seeks to support strategies and service models that will improve prevention, early identification and intervention, and treatment of mental health and substance use disorders, with an emphasis on children and older adults.

To be considered for a grant, applicants must address at least one of the Health Fund’s two cross-cutting goals:

1. Build, extend, and strengthen workforce capacity through training and development for clinicians, program staff, and informal caregivers. The Health Fund is specifically interested in proposals for new approaches to building, strengthening, and expanding the behavioral health workforce. This may include new models of team-based care, approaches to more effectively utilize providers or staff, or other approaches to expand a diverse and talented workforce.

2. Develop and expand innovative and cost-effective integration models that coordinate care, services, and community resources to promote the health of children and seniors in Michigan. The Health Fund is specifically interested in models that systematically integrate mental health, substance use, and medical care providers to meet all of a person’s health needs, no matter where they seek care. We also recognize the importance of integrating social needs into clinical care and encourage connections to community services and supports.

The Health Fund expects to award grants ranging from $100,000 to $500,000. An organization may not apply for a grant that is larger than 20% of its annual operating budget. No more than 10% of the total grant budget may be allocated to indirect/administrative costs. You may apply for a one or two-year grant, but the total request is limited to $500,000. Please be sure to clearly identify your funding requests per year in your proposal, along with any other associated program revenue.

March 15, 2018: Concept papers due by 5 p.m. (strongly encouraged)

NOTE: For U-M faculty interested in submitting a concept paper, please contact Colleen Sherman in the Michigan Medicine Office of Corporate & Foundation Relations - cols@med.umich.edu
Grantor: The Honorable Tina Brozman Foundation
Grant Opportunity: Research Grants
Keyword: Cancer; Chronic Diseases; Ovarian Cancer; Research Grant; Women’s Health
Award Amount: $200,000
Deadline: March 27, 2018

Request for Letters of Intent The Honorable Tina Brozman Foundation for Ovarian Cancer Research Individual Investigator Awards 2019-2020

https://tinaswish.org/

Purpose: The Honorable Tina Brozman Foundation (“Tina’s Wish”) is requesting Letters of Intent (LOI) for the Tina’s Wish individual investigator awards for 2019-20. Tina’s Wish awards annual grants to researchers proposing new ideas and concepts specifically for the early detection or prevention of ovarian cancer.

Funding:
1. Two-year grant.
2. The award’s annual total costs of $100,000 are inclusive of indirect costs, which should not exceed 10%.
3. The second year of funding is contingent on adequate progress during the first year.

LOI application deadline: Tuesday, March 27th, 2018 at 5pm Eastern time zone.

Grantor: Chordoma Foundation
Grant Opportunity: Research Grants
Keyword: Cancer; Chronic Diseases; Rare or Orphan Diseases; Research Grant
Award Amount: $150,000
Deadline: April 6, 2018

Chordoma Foundation and The Mark Foundation: Therapeutic Innovation Award

https://www.chordomafoundation.org/latest-updates/therapeutic-innovation-award/

The Chordoma Foundation is pleased to announce an exciting new funding opportunity aimed at accelerating the development of drug therapies targeting brachyury, a transcription factor that plays a key role in chordoma and other cancers.
Issued in partnership with The Mark Foundation for Cancer Research – which funds high-impact science that integrates biology with technology to deliver innovative breakthroughs to patients – the Therapeutic Innovation Award will be offered in two phases. The first funding phase will support a one-year pilot study to assess feasibility of an approach and generate preliminary data. For this phase, applicants may request up to $150,000 over a 12-month funding period. Based on the results generated in the first funding phase, awardees may be invited to apply for a second phase of funding which will support a multi-year continuation of the project.

The goal of this funding opportunity is to support innovative research that will explore novel approaches for targeting brachyury and lay the foundation for drug discovery efforts directed at disrupting the transcriptional pathways that drive cancer.

Relevant areas of study include but are not limited to:

Interaction of brachyury with other proteins and/or small molecules

Direct degradation of brachyury

Functional implications of the chordoma-associated SNP in brachyury

Therapeutic manipulation of upstream regulators of brachyury, or downstream brachyury targets

Immunogenic properties of brachyury

In particular, we are interested in proposals that apply emerging technologies from other scientific domains to chordoma and involve meaningful collaborations between investigators with complementary capabilities.

Letter of Intent (LOI) due: April 6, 2018

Grantor: Cystinosis Research Foundation

Grant Opportunity: Research Grants and Postdoctoral Research Fellowships

Keyword: Basic Science; Chronic Diseases; Genetic Disorders; Post-Doctoral Fellowship; Rare or Orphan Diseases; Research Grant

Award Amount: $150,000

Deadline: April 16, 2018

Cystinosis Research Foundation Spring 2018 Call for Research Proposals and Postdoctoral Research Fellowships

https://www.cystinosisresearch.org/research/for-researchers/

The mission of the Cystinosis Research Foundation is to support bench, clinical and translational cystinosis research to find better treatments and a cure for cystinosis.
Research Proposals: The Cystinosis Research Foundation is pleased to announce its Spring 2018 Call for Research Proposals and Fellowships. The Cystinosis Research Foundation is prepared to fund proposals to improve the immediate care of children and adults with cystinosis and to develop a new understanding and treatment of cystinosis in an effort to help these patients in the future.

Postdoctoral Fellowships: The Cystinosis Research Foundation has launched a postdoctoral research fellowship program to attract qualified, promising investigators to establish careers in cystinosis research. The fellow’s stipend should be the usual amount for such a trainee at that institution. The total award cannot exceed $75,000 per year including overhead. Awards will generally be for a period of 1-2 years.

Currently, the Cystinosis Research Foundation has $2,500,000 available for research and fellowship grants. The number of awards and their value will depend on the number of outstanding proposals and the funds available at the time.

The deadline for the spring 2018 grant proposals and fellowship applications is Monday, April 16, 2018.

Grantor: National Colorectal Cancer Roundtable
Grant Opportunity: Program Funding
Keyword: Cancer; Chronic Diseases
Award Amount: $100,000
Deadline: March 23, 2018

Request for Proposal: Colorectal Cancer Screening Links of Care Web-Based Training

http://nccrt.org/rfp-loc/

The NCCRT is pleased to announce a request for proposals to develop a web-based training to share best practices and lessons learned from the NCCRT’s three Links of Care pilots. The Links of Care pilots, launched in 2014, sought to strengthen the relationships between community health centers and the medical neighborhood in the delivery of colorectal cancer screening and follow up care. Our goal is to provide additional local communities with an online learning solution to find the tools needed to promote collaboration between health centers and specialty providers to improve the delivery of colorectal cancer screening and secure follow up care for patients in need.

The estimated budget should range from $75,000 to $100,000, which should include personnel and administrative costs.
Email notification of intent to apply and questions regarding the proposal are due March 23, 2018. The deadline for proposals is April 6, 2018.

Grantor: Propionic Acidemia Foundation
Grant Opportunity: Postdoctoral Fellowships and Research Grants
Keyword: Basic Science; Chronic Diseases; Genetic Disorders; Post-Doctoral Fellowship; Rare or Orphan Diseases; Research Grant
Award Amount: $100,000
Deadline: October 1, 2018

Request for Proposals on Propionic Acidemia

http://www.pafoundation.com/grants-how-to-apply/

Primary Research Mission: PAF is a non-profit organization whose primary mission is to help advance research devoted to find treatments and a cure for propionic acidemia. By funding research, we aim to gain new knowledge that can one day be translated into effective cures for all the children and adults affected by PA.

Application categories:
1) Research Projects – Basic and Clinical research
Awards range from $5,000-50,000 per year and may last 1 or 2 years upon competitive renewal.
This program funds research in the areas of basic and clinical science, supporting projects designed to understand the molecular basis of the PA pathology and explore possible therapeutic avenues for the treatment of this condition.
PAF is particularly, but not exclusively, interested in the following areas of research:
Improved treatment protocols including nutrition
Development of chelating compounds for PA toxicity
Risk factors for brain damage in PA
Risk factors for development of pancreatitis in PA
Risk factors for development of cardiomyopathy and/or arrhythmias in PA
Disease modifiers in PA
Development of new therapies and treatment
2) Fellows Program
This program provides financial support up to $50,000 per one year for a metabolic/genetic fellow working on a research project in PA. This salary is intended to supplement any existing institutional support for the trainee.

Submission Deadline: October 1, 2018

Grantor: National Psoriasis Foundation
Grant Opportunity: Research Grants
Keyword: Chronic Diseases; Dermatology; Research Grant
Award Amount: $100,000
Deadline: Rolling

National Psoriasis Foundation Request for Proposals: Bridge Grants

https://www.psoriasis.org/grants

Bridge Grants support researchers who have submitted meritorious but unsuccessful K- and R-applications to the National Institutes of Health with a focus on psoriatic disease or related comorbidities. Through this special opportunity, NPF provides a critical year of additional support to near-miss applicants so that they can collect data to strengthen a future application. Applicants may request up to $50,000 for K-bridge or $100,000 for R-bridge for one year.

Applications will be accepted year-round.

Grantor: Bee Foundation
Grant Opportunity: Research Grants
Keyword: Aneurysm; Cardiovascular; Research Grant
Award Amount: $50,000
Deadline: April 20, 2018

Request for Proposals: Brain Aneurysm Research Grant

http://www.thebeefoundation.org/brain-aneurysm-research-grant/

The Bee Foundation (TBF) invites proposals for this brain aneurysm research grant that further the mission of reducing the number of deaths caused by brain aneurysms. Proposals directed at understanding the early detection, pathophysiology, genetic predisposition, or treatment will take priority. Proposals from a variety of disciplines (including but not limited to translational
Only.

Neurosciences, neurosurgery, neurology, radiology, and genetics) are encouraged, and multidisciplinary proposals that illustrate a multi-faceted approach will be weighted highly.

$25,000 – $50,000 total amount to be distributed, but not limited to only 1 awarded applicant

Applicants may request up to $50,000

Application Due Date: April 20, 2018

Grantor: Children's Cardiomyopathy Foundation
Grant Opportunity: Seed Funding
Keyword: Congenital Heart Defects; Chronic Diseases; Research Grant
Award Amount: $50,000
Deadline: June 13, 2018

Children's Cardiomyopathy Foundation Research Grant Program

http://www.childrenscardiomyopathy.org/site/grants.php

CCF's grant program is designed to provide seed funding to investigators for the testing of initial hypotheses and collecting of preliminary data to help secure long-term funding by the National Institutes of Health and other major granting institutions.

Funding: Funding is available in the range of US$25,000 to US$50,000 for one year of total direct costs. Following the completion of the proposed study, a second year of funding may be requested by application. Upon receipt of a signed CCF letter of agreement and IRB or IACUC approval, CCF will disburse funds in installments during the grant period.

Application Process: CCF requires a letter of intent in advance of the grant application. The 2018 deadline for letters of intent is Wednesday, June 13 by 5:00 pm eastern standard time.

Grantor: Tell Every Amazing Lady About Ovarian Cancer Louisa M. McGregor Ovarian Cancer Foundation
Grant Opportunity: Research Grants
Keyword: Cancer; Chronic Diseases; Ovarian Cancer; Research Grant: Women’s Health
Award Amount: $50,000
Deadline: May 31, 2018
Tell Every Amazing Lady About Ovarian Cancer Louisa M. McGregor Ovarian Cancer Foundation 2018 Medical Research Program

https://docs.google.com/forms/d/e/1FAIpQLSfK2B12ytSRAGGreT42OWysQy-xR5BQFeDQ6gYNzzh98yXeig/viewform

The Tell Every Amazing Lady About Ovarian Cancer Louisa M. McGregor Ovarian Cancer Foundation 2018 Medical Research Program offers funding in support of ovarian cancer research studies that are most aligned with that mission as determined by the T.E.A.L. board of directors and scientific advisory board.

The mission of the T.E.A.L. is to promote public awareness of and education about the signs, symptoms, and risk factors of ovarian cancer, provide support to survivors, and raise funds for research in order to find a cure.

In 2018, T.E.A.L. will award one-year grants of up to $50,000.

The deadline to submit proposals is May 31, 2018.

Grantor: Pfizer
Grant Opportunity: Research Grants
Keyword: Basic Science; Chronic Diseases; Rare or Orphan Diseases; Research Grant
Award Amount: $50,000
Deadline: May 14, 2018

Request for Proposals: 2018 Global ASPIRE Transthyretin (TTR) Amyloidosis Competitive Research Grant Awards for Junior Investigators

https://www.aspirereseach.org/TTRFAP/index.html

The Global ASPIRE TTR amyloidosis program underscores Pfizer’s commitment to supporting investigators with an interest in advancing their academic research in TTR amyloidosis.

Mission

The mission of the GLOBAL ASPIRE TTR amyloidosis program is as follows:

To support specific research in basic science and broad clinical research through a competitive grants program that advances medical knowledge in the understanding, diagnosis and treatment of TTR amyloidosis. In-scope research submissions along the entire clinical spectrum of TTR amyloidosis (from TTR familial amyloid polyneuropathy (TTR-FAP) to TTR cardiomyopathy) and including mixed phenotypes are highly encouraged.
Although recent developments have been made in the diagnosis and treatment of TTR amyloidosis, more research is needed. The goal of the 2018 GLOBAL ASPIRE TTR amyloidosis program is to further improve our understanding of the epidemiology, basic science and early diagnosis and treatment of TTR amyloidosis.

Request for Proposals: Pfizer invites junior investigators with a terminal degree (MD and/or PhD and/or PharmD or equivalent) who are developing their research careers in TTR Amyloidosis to apply for the 2018 GLOBAL ASPIRE Awards in TTR amyloidosis through submission of innovative research proposals designed to enhance our ability to understand the epidemiology, basic science and early diagnosis and treatment of patients with TTR amyloidosis.

2018 Research Topics: Epidemiology, Basic Science and Tools for Early Diagnosis and Treatment of Patients with TTR Amyloidosis.

2018 Areas of Research Interest

Research Requirements: Pfizer is interested in supporting research proposals that advance our understanding of the epidemiology, basic science and early diagnosis and treatment of TTR amyloidosis through research focused in the following areas:

Epidemiologic evaluations for TTR amyloidosis
Global or regionally-focused evaluations
Approaches for the early diagnosis of patients including:
Multidisciplinary approaches
New diagnostic algorithms
Imaging studies
Non-invasive diagnostic techniques
Autonomic markers of TTR-FAP disease progression
Risk factors for disease penetrance
Markers of disease progression and natural history studies
Genetic screening programs for families
Genetic counseling patient support tools
Evaluation of patients with TTR amyloidosis presenting with a mixed phenotype (e.g. polyneuropathy and cardiomyopathy) and including studies of patients with nonV30M mutations
Case Control and Cross-Sectional Studies
Includes examination of phenotype and genotype relationships
Evaluating Existing Databases for:
Clinical or treatment information
Phenotype or genomic factors
Retrospective analyses of the long-term efficacy and safety of tafamidis in the clinical setting for the management of TTR-FAP
Impact on disease progression and quality of life
Includes prospective or retrospective evaluations based on the tafamidis real world experience in clinical practice
Note: Pfizer will not supply formulated study drug
Mechanistic studies to advance the basic science of amyloid formation and deposition

Available Awards: This program is exclusively open to junior investigators from around the world who have a terminal degree (MD and/or PhD and/or PharmD or equivalent) and are developing their research careers in TTR Amyloidosis. Pfizer is funding research awards ranging from $25,000 USD to a maximum of $50,000 USD each.
Application deadline: May 14, 2018 (by 11:59pm EST in the United States)

Grantor: National Cancer Center
Grant Opportunity: Postdoctoral Fellowships
Keyword: Basic Science; Cancer; Chronic Diseases; Post-Doctoral Fellowship
Award Amount: $40,000
Deadline: December 18, 2018
National Cancer Center Post-Doctoral Fellowships

http://nationalcancercenter.org/NCC_Grant.html

National Cancer Center has established funding for a limited number of post-doctoral fellowships for qualified applicants to receive training and experience in molecular genetics and the cellular aspects of cancer biology and tumor immunology.
Funding is also available for post-doctoral fellowships in children's cancer research, including fighting children's leukemia.
Preference will be given to studies that have direct relevance to the diagnosis and treatment of human cancer. Fellowships from NCC are established at $40,000 per annum for post-doctoral awards.
Fellowships generally are extended for a second year. However, adequate progress must have been demonstrated during the first year as evidenced through a progress report submitted with renewal application.

Awards are limited to one per laboratory. There can be several different applications if they are on different topics. However, only one award could be made per lab in any round of applications.

Deadline for application, to be received in Plainview, New York, is on December 18, 2018.

Grantor: Albert and Mary Lasker Foundation
Grant Opportunity: Essay Contest
Keyword: Prizes
Award Amount: Not Specified
Deadline: March 30, 2018

Albert and Mary Lasker Foundation 2018 Essay Contest


Essay Topic:  How can social media help build trust in science and the research enterprise? Your answer should include a discussion of the benefits and challenges of your recommendations.

We invite you to submit an essay of 800 words or less, written in English. Figures and references are not required but applicants are welcome to include one image (uploaded separately) and up to 10 references (at the end of the text body) with their essay.

The deadline to submit all materials is March 30, 2018.

Grantor: Merck & Co., Inc.
Grant Opportunity: Research Grants
Keyword: Chronic Diseases; Inflammatory Bowel Disease; Pharmaceutical; Research Grant; Rheumatology
Award Amount: Not Specified
Deadline: May 14, 2018

Biosimilars - Immunology Investigator Studies Program
http://engagezone.msd.com/biosimilars-immunology.php

Effective January 2018, the Biosimilars - Immunology Investigator Studies Program (MISP) Committee will accept proposals within our current areas of interest (AOI) up to May 14, 2018.

The following areas are of interest to Investigator Studies Program Committee:

Studies to evaluate the effectiveness of SB/Merck’s Infliximab for patients with Ankylosing Spondylitis (AS) or Inflammatory Bowel Disease (IBD) (including multi switch studies between Merck/Samsung Biosimilar and Originator and studies including TDM)

Studies to evaluate Biosimilar to Biosimilar switches between different infliximab biosimilars on Inflammatory Bowel Disease (IBD)

Studies to evaluate the impact of biosimilar education on healthcare provider and patient acceptance for biosimilars

Full Protocol Submission with Detailed Budget: May 14, 2018

Grantor: Merck & Co., Inc.

Grant Opportunity: Research Grants

Keyword: Basic Science; Chronic Diseases; Diabetes; Diabetes -Type II; Pharmaceutical; Research Grant

Award Amount: Not Specified

Deadline: Rolling

Diabetes and Metabolism Investigator Studies Program


The Diabetes and Metabolism Investigator Studies Program (MISP) Committee will accept proposals within our current areas of interest (AOI) on a rolling basis. Reviews will occur on a monthly basis in 2018.

The following areas are of interest to the Investigator Studies Program Committee:

Metabolic effects of DPP-4 inhibitors beyond glucose metabolism

Use and effects of DPP-4 inhibitors in the real world (e.g., ease of utilization, patient preference, combination use with other drug classes)

Impact of adding/switching within and across classes of anti-hyperglycemic medications on adherence, compliance, and outcomes
Clinical and mechanistic studies regarding the effects of SGLT-2 inhibition on macrovascular complications including heart failure in T2DM (e.g. echocardiographic assessment of cardiac function, cardiac energetics, cardiac substrate utilization)

Clinical and mechanistic studies regarding the effects of SGLT-2 inhibition on kidney disease in T2DM

Clinical and mechanistic studies regarding the effects of SGLT-2 inhibition on other comorbidities frequently associated with T2DM

Clinical and mechanistic studies regarding the effects of SGLT-2 inhibition, alone and in combination with DPP-4 inhibitors, on metabolic control and the cardio-renal-axis in T2DM

Mechanisms regulating glucagon secretion in T2DM and the impact of treatment modalities

Effect of glucagon, alone and in combination with GLP-1, on human energy balance

Effect of glucagon, alone and in combination with GLP-1, on non-alcoholic fatty liver disease in humans

Predictive value of continuous glucose monitoring for event rates of hypoglycemia

Grantor: Merck & Co., Inc.

Grant Opportunity: Research Grants

Keyword: Acute Care; Infectious Disease; Quality Improvement; Research Grant

Award Amount: Not Specified

Deadline: May 1, 2018

Antimicrobial Stewardship Investigator Studies Program

http://engagezone.msd.com/Antimicrobial_Stewardship.php

Effective January 2018, the Antimicrobial Stewardship Investigator Studies Program (MISP) Committee will accept proposals within our current areas of interest (AOI) up to May 1, 2018.

The following areas are of interest to Investigator Studies Program Committee:

Antimicrobial stewardship programs (ASPs) in alternative settings transitions of care, and/or special populations

Integration of ASPs across integrated delivery networks (IDNs), accountable care organizations (ACOs), or ASP practices in regions with unmet need

Identifying risk factors/drivers for inappropriate antimicrobial use decisions
Use of clinical decisions support within electronic medical records and/or telemedicine for ASPs

Use of rapid diagnostics for ASPs

Behavioral and implementation sciences relative to the conduct of ASPs

Evaluation of the impact of ASP intervention(s) on outcomes that may include, but are not limited to, the following:

Patient outcomes (e.g. length of stay, readmission, mortality)

Unintended consequences of antibiotic use (e.g. toxicity, resistance, selection of pathogenic organisms, effects on microbiome)

Process measures (e.g. appropriateness of antimicrobial use, time to active/appropriate therapy, guideline adherence)

Full Proposal Submission & Detailed Budget: May 1, 2018

Grantor: Merck & Co., Inc.

Grant Opportunity: Research Grants

Keyword: Acute Care; Infectious Disease; Quality Improvement; Research Grant

Award Amount: Not Specified

Deadline: August 1, 2018

Antibacterial Investigator Studies Program


Effective January 2018, the Antibacterial Investigator Studies Program (MISP) Committee will accept proposals within our current areas of interest (AOI) up to Aug 1, 2018 for the second review cycle.

The following areas are of interest to the Investigator Studies Program Committee:

Tedizolid Phosphate

Assessment of tedizolid treatment and tolerability in populations with limited data in the Phase 3 program including but not limited to:
Step down from standard of care IV therapy to tedizolid for susceptible MRSA, MSSA, or VRE infections (e.g., but not limited to: early discharge management, uncomplicated blood stream or SSTI management, outpatient intervention avoiding acute hospitalization)

Infections in patients with diabetes mellitus or other immunocompromised conditions

Health economics and outcomes research of the use of tedizolid phosphate in patient populations described in the above settings, in optimizing patient outcomes and healthcare utilization (e.g., but not limited to: hospital early discharge management; impact on acute hospitalization or transfer from long-term care facility to acute care institution)

Assessment in other infections with susceptibility to tedizolid (e.g., but not limited to: non-tuberculous mycobacteria)

Ceftolozane/Tazobactam

Clinical evaluation of ceftolozane/tazobactam for the treatment of proven or suspected infections in high-risk patient populations, including those with co-morbidities (e.g., immunosuppression), high-risk infection types, and/or multi-resistant pathogens

Use of ceftolozane/tazobactam in accordance with institutional antimicrobial stewardship guidance

Pharmacoeconomic, health economic and/or outcomes research studies of ceftolozane/tazobactam

In-vitro susceptibility/activity of ceftolozane/tazobactam against clinical isolates obtained from clinically relevant patient populations across geographic regions

Imipenem-cilastatin-relebactam (MK-7655, BLI)

Preclinical studies of imipenem/relebactam activity, including PK/PD investigations, and/or in-vitro (including susceptibility, time-kill, or synergy studies)

In-vitro susceptibility/activity of imipenem/relebactam against clinical isolates obtained from high-risk patient populations (including but not limited to: hematology, transplant, intensive care, long-term acute care (LTAC) patients) and multi-drug resistant gram negative organisms

Molecular epidemiological studies of carbapenem resistance in Enterobacteriaceae and Pseudomonas aeruginosa
Studies that evaluate the cost and consequence of infections by multi-drug resistant (MDRO) Gram negative rods (specifically, carbapenem-resistant Enterobacteriaceae (CRE) and Pseudomonas aeruginosa)

2nd Review Cycle Full Proposal Submission & Detailed Budget: August 1, 2018

Grantor: Merck & Co., Inc.
Grant Opportunity: Research Grant
Keyword: Acute Care; Infectious Disease; Quality Improvement; Research Grant
Award Amount: Not Specified
Deadlines: June 1, 2018; August 31, 2018

Antibacterial Investigator Studies Program—Clostridium difficile

http://engagezone.msd.com/clostridium.php

Effective January 2018, the Antibacterial Investigator Studies Program (MISP) Committee will accept proposals within our current areas of interest (AOI) up to June 1, 2018 for the second review cycle, and up to August 31, 2018 for the third review cycle.

The following areas are of interest to Investigator Studies Program Committee:

Clinical evaluation and/or health economic and outcome research of bezlotoxumab added to standard of care therapy to reduce recurrence of CDI in patients at high-risk for recurrence or populations under-represented or not represented in the Phase 3 trials (e.g., but not limited to: patients with inflammatory bowel disease, immunocompromised)

Clinical evaluation and/or health economic and outcome research of bezlotoxumab efficacy in secondary prevention in patients who had a prior CDI episode and are at risk for a new CDI episode (e.g., but not limited to: exposure to broad spectrum antibiotics, residents in long-term care facilities). This may include patients who had received bezlotoxumab during treatment of a prior episode.

Studies aimed at further understanding the mechanisms of action of bezlotoxumab in clostridium difficile associated diarrhea. (e.g., but not limited to: understanding of bezlotoxumab in passive neutralization of toxin B as compared to the active inhibition of the production of toxin B by fidaxomicin)

Use of fidaxomicin and/or bezlotoxumab in clinical pathways for CDI and recurrent CDI

Full Proposal Submission & Detailed Budget:
ONLY.

2nd Review Cycle: June 1, 2018; 3rd Review Cycle August 31, 2018

Grantor: Merck & Co., Inc.
Grant Opportunity: Research Grants
Keyword: Acute Care; HIV/AIDS; Quality Improvement; Research Grant
Award Amount: Not Specified
Deadlines: June 1, 2018; August 31, 2018

CMV Investigator Studies Program

http://engagezone.msd.com/cmv.php

Effective January 2018, the CMV Investigator Studies Program (MISP) Committee will accept proposals within our current areas of interest (AOI) up to June 1, 2018 for the second review cycle, and up to August 31, 2018 for the third review cycle.

The following areas are of interest to Investigator Studies Program Committee

Observational studies in solid organ transplant (SOT) recipients describing unmet needs in the prevention of CMV, including (but not limited to the burden of disease, impact of CMV infection/reactivation on organ and patient outcomes, limitations or prophylaxis with DNA polymerase inhibitors, novel methods to identify or define cases of antiviral toxicity

Burden of illness/Epidemiology of illness outside HSCT and SOT

Studies aimed at biomarkers or other testing to evaluate the host and/or viral response to letermovir, and that may elucidate the pathology or early CMV reactivation

Understanding the terminase inhibitor mechanism of action including but not limited to the impact on viral dynamics DNA polymerase/thymidine kinase inhibitor agents, and the impact on the host immune response to CMV

Further understanding the mechanisms of resistance to letermovir and how may these be overcome

Clinical

Studies to optimize prophylaxis strategies in immunocompromised patients (for example but not limited to):

HSCT:
Timing of initiation of prophylaxis

Re-initiation of prophylaxis in patients who are at high risk of CMV reactivation post initial prophylaxis course

Studies of impact of CMV suppression in patients with diseases where CMV infection may play a role (for example but not limited to: HIV, non-transplant immunosuppressed patient populations, ICU populations, etc.)

Full Protocol Submission with Detailed Budget

2nd Review Cycle: Jun 01, 2018
3rd Review Cycle: Aug 31, 2018

Grantor: Merck & Co., Inc.
Grant Opportunity: Research Grants
Keyword: Acute Care; Quality Improvement; Research Grant
Award Amount: Not Specified
Deadlines: April 2, 2018; June 1, 2018; September 7, 2018

Antifungal Investigator Studies Program


Effective August 2017, the Antifungal Investigator Studies Program (MISP) Committee will accept proposals within our current areas of interest (AOI) up to April 2, 2018 for the first review cycle, up to June 1, 2018 for the second review cycle, and up to September 7, 2018 for the third review cycle.

The following areas are of interest to the Investigator Studies Program Committee:

Noxafil/posaconazole

Clinical experience with posaconazole (with either the oral suspension, oral tablet, and/or IV solution) either in prophylaxis or treatment (including salvage treatment) of hematopoietic stem cell transplant patients (including patients with GVHD), neutropenic patients with hematologic malignancies post –chemotherapy, solid organ transplant recipients and other immunosuppressed patients (including use in the ICU setting).
Preclinical studies including global and regional azole susceptibility surveys, mechanisms of azole resistance, in vitro and in vivo models of relevant invasive mold infections, and PK/PD assessments in relevant invasive mold infections.

PK/PD assessment of Posaconazole (IV, tablet, IV-to-tablet) in special populations

Epidemiological studies evaluating burden of disease of Candida and Aspergillus or other rare mold infections in high risk patient populations

Pharmacoeconomic, health services and/or outcomes research studies in approved indications

Antifungal Stewardship initiatives that explore the utility of Posaconazole

Full Proposal Submission & Detailed Budget

1st Review Cycle: April 2, 2018
2nd Review Cycle: June 1, 2018
3rd Review Cycle: September 7, 2018

Grantor: Merck & Co., Inc.

Grant Opportunity: Research Grants

Keyword: Chronic Diseases; HIV/AIDS; Infectious Disease; Quality Improvement; Research Grant

Award Amount: Not Specified

Deadline: March 30, 2018

HIV Investigator Studies Program

http://engagezone.msd.com/HIV.php

The following areas are of interest to Investigator Studies Program Committee:

Optimizing ARV regimens for the management of HIV to facilitate treatment of HIV infected individuals including but not limited to patients at risk for co-morbidities and toxicities, such as: CNS disease, cardiovascular disease, hyperlipidemia, hepatic dysfunction, renal abnormalities. Establish the efficacy and safety in larger numbers of patients in these groups, which have been underrepresented in clinical trials and increasingly comprise the majority of treated patients.

Special populations: Different races and ethnicities, aging patients, and women. Establish the efficacy and safety in larger numbers of patients in these groups, which have been underrepresented in clinical trials and increasingly comprise the majority of treated patients.
Investigate the impact of HIV and aging on reproductive health (pregnancy, menopause, contraception)

Co-infection: Tolerability and ease of use of Merck product containing regimens in patients who require treatment for co-infection with drugs that often cannot be used with many ARVs such as HIV patients co-infected with HCV, TB or HBV.

Drug Drug Interactions focusing on potential interactions between Merck products and drugs used to treat underlying conditions such as: cardiovascular disease, hypertension, diabetes, bone disease, neuroaffective disorders.

Pathogenesis: Inflammation and biomarkers, eradication and viral reservoirs.

HIV Resistance: Characterization of transmitted resistance; patterns of emergence of resistance and prevalence, especially in Non B subtypes; emergence of resistance in patients failing prior regimens; and efficacy in patients with viral resistance.

Full Protocol Submission with Detailed Budget: March 30, 2018

Grantor: Merck & Co., Inc.
Grant Opportunity: Research Grants
Keyword: Alzheimer's Disease & Other Dementias; Chronic Diseases; Disparities; Neurological Disorders; Quality Improvement; Research Grant
Award Amount: Not Specified
Deadline: April 20, 2018

Alzheimer's Disease Investigator Studies Program


Effective December 2017, the Alzheimer's Disease Investigator Studies Program (MISP) Committee will accept proposals within our current areas of interest (AOI) up to April 20, 2018.

The following areas are of interest to the Investigator Studies Program Committee for Non-Drug studies:

BRAIN HEALTH: Studies examining the benefit of brain health awareness and advocacy (e.g. early baseline cognitive screening)

RECRUITMENT: Studies designed to explore factors that drive engagement of future trial participants in the preclinical stage of Alzheimer’s Disease

EARLY DETECTION/DIAGNOSIS: Studies investigating
phenotypes of risk (ethnicity, genetic, biochemical, imaging, subjective memory complaints, comorbidities, etc.) that may help identify and allow early diagnosis of individuals who will progress to Alzheimer’s Disease dementia

methodologies for measuring change (e.g., cognition, function, tau markers) in pre-symptomatic individuals with increased risk for Alzheimer’s Disease

novel diagnostic methodologies to case-find/screen for prodromal, Mild Cognitive Impairment or earlier stages of Alzheimer’s Disease in clinical practice and for monitoring of disease progression

BIOMARKERS:

Studies of molecular markers of neuroinflammation and neurodegeneration related to amyloid and tau dysregulation (e.g., measures of clearance and production that may predict amyloid accumulation)

Studies using remote data sensing to construct digital biomarkers associated with early detection of Alzheimer’s disease and/or progression through stages of Alzheimer’s Disease

DISEASE PROGRESSION: Studies relating to early changes in interpersonal dynamics and behavioral changes in people with Alzheimer’s Disease

PATIENT PATHWAY: Studies investigating novel care pathways with value-based healthcare solutions (e.g. for early diagnosis and non-pharmacological disease management) in patients with Mild Cognitive Impairment due to Alzheimer’s Disease

DISPARITY: Studies investigating racial/ethnic disparities in dementia incidence, diagnosis, treatment and health outcomes

Full Protocol Submission / Detailed Budget: April 20, 2018

Grantor: Merck & Co., Inc.
Grant Opportunity: Research Grants
Keyword: Device & Robotics; Research Grant; Sleep Research
Award Amount: Not Specified
Deadlines: March 23, 2018; June 22, 2018

Insomnia Investigator Studies Program

http://engagezone.msd.com/insomnia.php
Effective December 2017, the Insomnia Investigator Studies Program (MISP) Committee will accept proposals within our current areas of interest (AOI) up to March 23, 2018 for the first review cycle and up to June 22, 2018 for the second review cycle.

The following areas are of interest to the Investigator Studies Program Committee:

Human studies that characterize differentiating attributes of orexin receptor antagonism mechanism of action

Studies investigating the optimal treatment of insomnia, treatment patterns and real world use of an orexin receptor antagonist in a clinical practice setting across various patient archetypes/subpopulations

Studies investigating measures to assess severity and impact of insomnia (e.g. next day function)

Studies investigating how suvorexant can be effectively used as part of an integrated treatment plan for insomnia including behavioral therapies (e.g., CBT-I)

Studies assessing the utility of validated mobile devices, wearables and other remote sensing device/data technology for characterizing insomnia and treatment outcomes

Nonclinical studies comparing sleep promoting mechanisms with a focus on translational functional measures related to insomnia

Full Protocol Submission / Detailed Budget

1st Review Cycle: March 23, 2018

2nd Review Cycle: June 22, 2018

Grantor: Merck & Co., Inc.

Grant Opportunity: Research Grants

Keyword: Cancer; Chronic Diseases; Immuno-oncology; Leukemia & Lymphoma; Ovarian Cancer; Prostrate Cancer; Research Grant

Award Amount: Not Specified

Deadline: September 7, 2018

Oncology Translational Studies Program (OTSP)

http://engagezone.msd.com/otsp.php

Effective September 2017, the OTSP Committee will accept proposals within our current areas of interest (AOI) up to September 7, 2018 for the second review cycle.
We seek to understand factors responsible for responsiveness and resistance to immunotherapy. Submissions may focus on either retrospective or prospective evaluation of human samples, must have either primary translational or co-primary translational/clinical endpoints, and require an appropriately powered translational research hypothesis addressing one or more of the subject areas below.

Effects of intra-tumoral myeloid populations on the anti-tumor immune response

Effects of cancer associated fibroblasts and other stromal populations on anti-tumor immune response

Mechanisms of immune escape in the setting of active immunotherapy leading to acquired resistance.

Subcategorizing and working to understand mechanisms of primary resistance

Metabolic effectors (in tumor and/or immune cells) relevant to the anti-tumor immune response

Understanding effects of B cell biology on response to immunotherapy

Proposals should address this biology with innovative, focused, hypothesis-driven approaches, must involve usage of pembrolizumab alone or in combination in the study design, and must not be purely in vitro or in mouse models. Proposals in all cancer indications are welcome. Proposals in prostate cancer, ovarian cancer, MSS colorectal cancer, and diffuse large B cell lymphoma are of particular interest, as are studies focused on identifying strong peripheral and/or other non-invasive biomarkers of response.

2nd Review Cycle Pre-review deadline: September 7, 2018

Grantor: Merck & Co., Inc.

Grant Opportunity: Research Grants

Keyword: Disparities; Health Policy & Research; Quality Improvement; Research Grant

Award Amount: Not Specified

Deadline: May 16, 2018

Patient Engagement, Diversity and Health Literacy Investigator Studies Program

http://engagezone.msd.com/Patient_Engagement_Diversity_Health_Literacy.php

Effective January 2018, the Patient Engagement, Diversity and Health Literacy Investigator Studies Program (MISP) Committee will accept proposals within our current areas of interest (AOI) up to May 16, 2018.

The following areas are of interest to Investigator Studies Program Committee:
Science of Patient Engagement/Input:

Studies to evaluate the effectiveness of quantitative or qualitative tools, methods or processes to deliver new, sustainable approaches/standards for patient engagement or insights along the continuum of medicines’ development.

Studies to evaluate the benefits (improvement in efficiency, effectiveness, or diversity) of engaging patients along the continuum of medicines’ development.

Diversity and Inclusion/Population Health:

Studies to evaluate the effectiveness and/or scalability of novel approaches to increasing clinical trial diversity.

Health Literacy Areas of Interest:

Studies evaluating the benefits (improved health behaviors or health outcomes) of addressing health literacy, by reducing complexity for patients, and/or by addressing provider communication or other system issues.

Studies that assess and/or test digital health literacy assessment tools used in online surveys or research designed to increase participation of low health literacy individuals.

Concept/Protocol Submission with Detailed Budget: May 16, 2018

Grantor: Merck & Co., Inc.

Grant Opportunity: Research Grants

Keyword: Acute Care; Quality Improvement; Research Grant; Surgery

Award Amount: Not Specified

Deadlines: May 1, 2018; July 2, 2018; September 4, 2018

Surgery Investigator Studies Program—Anesthesia

http://engagezone.msd.com/anesthesia.php

Effective September 2017, the Surgery Investigator Studies Program (MISP) Committee will accept proposals within our current areas of interest (AOI) as noted below.

The following areas are of interest to the Investigator Studies Program Committee:

NEUROMUSCULAR BLOCKADE (NMB):

Impact of NMB (including deep block) on surgical conditions and other intra-operative outcomes for a variety of procedures, especially abdominal minimally invasive, ENT, ocular, orthopedic joint manipulation, thoracic, and neurosurgical.
Impact of NMB (including deep block) on post-operative outcomes (see procedures above), including pulmonary, pain, nausea, vomiting, neurohumoral response, cardiac function, cognition, ambulation, swallowing, and overall patient satisfaction.

Impact of the addition of NMB (including deep block) to an enhanced recovery protocol.

depth block – post-tetanic count of 1 or twitches

RESIDUAL NMB:
Impact of residual NMB on postoperative recovery and/or other perioperative outcomes overall, and in special populations
Identify special populations at risk for postoperative pulmonary and other complications
Special populations include but are not limited to: children, elderly, obese, those with burns, those with pulmonary disease, those in special settings (intensive care, ambulatory, other), those with neuromuscular or psychiatric disorders
Impact of subjective vs. objective neuromuscular monitoring on achieving complete recovery at extubation and/or the rate of residual paralysis
Develop simple clinical methods to detect residual block

EFFICIENCY:
Impact of reversal of NMB on patient care efficiency, including:
time in the operating room, PACU, ICU, or hospital in various scenarios or in specific procedures
costs in various scenarios (inpatient; outpatient, other), patient populations (see #2), and procedures
Develop and/or validate methods to measure efficiency

ENHANCED RECOVERY PROTOCOLS:
Contribution of neuromuscular relaxant reversal and/or NMB (including deep block) on patient outcomes in specific surgical protocols (GI, bariatric, orthopedic, etc.)
Contribution of peripheral opioid receptor antagonists to the impact of a protocol

REAL WORLD EVIDENCE:
Impact of introduction of sugammadex on clinical behaviors and/or clinical practice, such as monitoring usage, reversal practice, use of specific anesthetic techniques or adjuvants
Full Protocol Submission with Detailed Budget

3rd Review Cycle: May 1, 2018
Effective September 2017, the Surgery Investigator Studies Program (MISP) Committee will accept proposals within our current areas of interest (AOI) as noted below.

The following areas are of interest to the Investigator Studies Program Committee:

**NEUROMUSCULAR BLOCKADE (NMB):**

- Impact of NMB (including deep block) on surgical conditions and other intra-operative outcomes for a variety of procedures, especially abdominal minimally invasive, ENT, ocular, orthopedic joint manipulation, thoracic, and neurosurgical
- Impact of NMB (including deep block) on post-operative outcomes (see procedures above), including pulmonary, pain, nausea, vomiting, neurohumoral response, cardiac function, cognition, ambulation, swallowing, and overall patient satisfaction.
- Impact of the addition of NMB (including deep block) to an enhanced recovery protocol.

**RESIDUAL NMB:**

- Impact of residual NMB on postoperative recovery and/or other perioperative outcomes overall, and in special populations.
- Identify special populations at risk for postoperative pulmonary and other complications.

Special populations include but are not limited to: children, elderly, obese, those with burns, those with pulmonary disease, those in special settings (intensive care, ambulatory, other), those with neuromuscular or psychiatric disorders.
Impact of subjective vs. objective neuromuscular monitoring on achieving complete recovery at extubation and/or the rate of residual paralysis

Develop simple clinical methods to detect residual block

EFFICIENCY:

Impact of reversal of NMB on patient care efficiency, including:

time in the operating room, PACU, ICU, or hospital in various scenarios or in specific procedures

costs in various scenarios (inpatient; outpatient, other), patient populations, and procedures

Develop and/or validate methods to measure efficiency

ENHANCED RECOVERY PROTOCOLS:

Contribution of neuromuscular relaxant reversal and/or NMB (including deep block) on patient outcomes in specific surgical protocols (GI, bariatric, orthopedic, etc.)

Contribution of peripheral opioid receptor antagonists to the impact of a protocol

REAL WORLD EVIDENCE:

Impact of introduction of sugammadex on clinical behaviors and/or clinical practice, such as monitoring usage, reversal practice, use of specific anesthetic techniques or adjuvants

Full Protocol Submission with Detailed Budget

3rd Review Cycle: May 1, 2018

4th Review Cycle: Jul 2, 2018

5th Review Cycle: Sep 4, 2018

Grantor: Merck & Co., Inc.

Grant Opportunity: Research Grants

Keyword: Acute Care; Infectious Disease; Pediatrics & Child Health; Quality Improvement; Research Grant; Vaccine

Award Amount: Not Specified

Deadline: June 25, 2018

CMV Vaccine Investigator Studies Program

http://engagezone.msd.com/cmv_vaccine.php
Effective January 2018, the CMV Vaccine Investigator Studies Program (MISP) Committee will accept proposals within our current areas of interest (AOI) up to June 25, 2018.

The following areas are of interest to Investigator Studies Program Committee:

Research that

- Estimations of the unmet medical need for cCMVi and cCMVd
- Documentation of the time for cCMVi hearing and visual loss to appear in infants born seropositive and asymptomatic
- Characterization of the specific patterns of cCMVi hearing/visual impairment (i.e., sudden hearing impact or is there a signature pattern of frequency loss, etc.)
- Exploration of shedding as a marker for cCMVi vertical transmission risk in seronegative AND seropositive mothers
- Are some infants infected with CMV at birth come born to mothers without demonstrable shedding in the urine or saliva?
- More data on whether quantitative level of virus is important
- Potential adverse impact of CMV reactivation on clinical outcomes in patients who are acutely hospitalized due to any cause
- Value of vaccine in reducing complication of CMV in SOT patients
- Estimation of cCMVi in seropositive women:
  - Maternal recurrent CMVi incidence during pregnancy: overall rate, reinfection vs. reactivation
  - Transmission: risk magnitude and mechanisms
  - Day-care center study of infant/toddler/mother - Prospective cohort demonstrating infection of mother with strain that the toddler carries
  - Among those latently infected with CMV, explore the impact of challenge with a new strain of the virus on re-infection, re-activation, shedding, and immune responses

Full Protocol Submission with Detailed Budget: June 25, 2018

Grantor: Merck & Co., Inc.

Grant Opportunity: Research Grants

Keyword: Chronic Diseases; Infectious Disease; Public Health; Research Grant; Vaccine

Award Amount: Not Specified

Deadline: April 23, 2018
**HPV Investigator Studies Program**


Effective January 2018, the HPV Investigator Studies Program (MISP) Committee will accept proposals within our current areas of interest (AOI) up to April 23, 2018.

The following areas are of interest to Investigator Studies Program Committee:

Research that

Studies the use of social media or other tools to increase HPV vaccination series completion

Elucidates the pathogenesis of HPV-related oropharyngeal cancer (OPC) and the relevance of persistent oral infection as a surrogate endpoint for OPC

Studies the effectiveness of vaccinating women and men ages 27-45 years of age to prevent HPV persistent infection and disease where labeled

Pilots methods to demonstrate reducing prevalence of HPV infection and eventual elimination of high grade CIN and cervical cancer through HPV vaccination

Full Protocol Submission with Detailed Budget: April 23, 2018

Grantor: Merck & Co., Inc.

Grant Opportunity: Research Grants

Keyword: Chronic Diseases; Infectious Disease; Public Health; Research Grant; Vaccine

Award Amount: Not Specified

Deadline: May 1, 2018

**Measles, Mumps, Rubella & Varicella Investigator Studies Program**


Effective December 2017, the Measles, Mumps, Rubella & Varicella Investigator Studies Program (MISP) Committee will accept proposals within our current areas of interest (AOI) up to May 1, 2018.

The following areas are of interest to Investigator Studies Program Committee:

Studies on a third dose of measles, mumps, rubella vaccine (M-M-RTMII) focused upon:

Immunogenicity (humoral and cell-mediated) and safety in a non-outbreak situation, including immunogenicity against mumps
Effectiveness, safety, economics, and/or acceptability in an outbreak setting

Small scale studies that advance the understanding of mumps immunology and vaccine response with respect to:

In vitro correlates of immune protection against mumps disease,

Evaluation of effect of circulating mumps genotype on vaccine efficacy/effectiveness

Persistence of immunity

Studies of persistence of immunity to measles, mumps, rubella and varicella, especially in populations with high vaccination rates.

Studies evaluating the burden of illness of varicella in regions, countries or populations in which these data are limited.

Full Protocol Submission / Detailed Budget: May 1, 2018

Grantor: Merck & Co., Inc.

Grant Opportunity: Research Grants

Keyword: Basic Science; Public Health; Research Grant; Vaccine

Award Amount: Not Specified

Deadline: May 1, 2018

Pneumococcus Investigator Studies Program

http://engagezone.msd.com/pneumococcus.php

Effective December 2017, the Pneumococcus Investigator Studies Program (MISP) Committee will accept proposals within our current areas of interest (AOI) up to May 1, 2018.

The following areas are of interest to Investigator Studies Program Committee:

Non-invasive diagnostic methods to reliably identify pneumococcal serotypes causing disease, with particular focus on non-bacteremic pneumonia in adults, and acute otitis media and pneumonia in infants.

Studies in a suitable animal model to investigate the factors associated with the pathogenesis of pneumococcal disease (invasive and noninvasive) in the setting of pneumococcal carriage.

Identification of pneumococcal molecular determinants associated with pneumococcal disease in the context of co-infection with other viral or bacterial pathogens as well as other conditions associated with increased risk for pneumococcal disease.
The prevalence, virulence and antibiotic resistance of serotypes 22F and 33F.

The epidemiology of the pneumococcal serotypes contained in PPV23, in settings/countries in which PCV 13 has been introduced, for all age groups, and where data are currently limited.

The rates of barriers to and facilitators of completion of sequential vaccination with PCV and PPV in adults.

The impact of environmental exposures, such as smoke, and air pollution, on the prevalence and serotype distribution of nasopharyngeal carriage and pneumococcal disease in children and adults.

Generation of Immunological memory and durability of protective responses for conjugate and non-conjugated polysaccharide vaccines.

These studies further stratified according to subject populations e.g., elderly and infants.

Studies evaluating the epidemiology, burden of illness and health-economic burden of Pneumococcal serotypes in regions, countries or populations in which these date are limited.

Particularly with regard to serotypes 22F and 33F.

Particularly serotype epidemiology in unstudied settings in which PCV13 has been introduced, stratified by age.

The prevalence and/or serotype distribution of pneumococcal carriage, risk factors for pneumococcal carriage, and the links between pneumococcal carriage and disease.

Studies that advance the understanding of immunology and vaccine response with respect to correlates of immune protection against pneumococcal disease in adults.

Studies evaluating the need for, efficacy, safety health economic impact and population-level impact of revaccination of PPV23.

Full Protocol Submission with Detailed Budget: May 1, 2018

Grantor: Merck & Co., Inc.
Grant Opportunity: Research Grants
Keyword: Health Policy & Research; Public Health; Research Grant; Vaccine
Award Amount: Not Specified
Deadline: May 1, 2018

Investigator Studies Program—Public Health & General Vaccinology

Effective December 2017, the Investigator Studies Program (MISP) Committee will accept proposals within our current areas of interest (AOI) up to May 1, 2018.

The following areas are of interest to Investigator Studies Program Committee:

Sustainable interventions, to improve rates of adolescent vaccination (including human papillomavirus) or adult vaccination (e.g. pneumococcal disease, herpes zoster, hepatitis B), in accordance with recommendations in other populations (e.g. minority populations in the US).

Studies of alternative strategies for vaccination via non-physician health care providers or unconventional vaccination sites (e.g., work places, social centers) to enhance appropriate immunization practices in accordance with existing recommendations, e.g. Advisory Committee on Immunization Practices.

How media reports related to vaccination affect public confidence in vaccines. Studies should address the impact of media reports on vaccination beliefs/uptake in a country or region, and assess the mechanisms used to effect beneficial changes in vaccination confidence (e.g., social media, family networks, governmental/policy outreach) -with the intent of drawing generalizable findings.

Evaluation of interventions in the provider, office setting, in order to support more effective provider communication and vaccine utilization, in accordance with national recommendations.

Evaluation of health system policy interventions to improve adult or adolescent vaccination rates.

Full Protocol Submission / Detailed Budget: May 1, 2018

Grantor: Merck & Co., Inc.
Grant Opportunity: Research Grants
Keyword: Public Health; Research Grant; Vaccine
Award Amount: Not Specified
Deadline: May 1, 2018

Rotavirus Investigator Studies Program

http://engagezone.msd.com/rotavirus.php

Effective December 2017, the Rotavirus Investigator Studies Program (MISP) Committee will accept proposals within our current areas of interest (AOI) up to May 1, 2018.

The following areas are of interest to Investigator Studies Program Committee:

Investigation of strategies aiming to improve vaccine efficacy of RotaTeq in low income settings
Studies to assess the reduction of gastroenteritis in areas where RotaTeq is widely used, where there is reasonable health care infrastructure to assess changes in disease burden, and where such data are currently limited.

Investigate indirect health benefits to RotaTeq vaccine

Full Protocol Submission with Detailed Budget: May 1, 2018

Grantor: Merck & Co., Inc.
Grant Opportunity: Research Grants
Keyword: Public Health; Research Grant; Vaccine
Award Amount: Not Specified
Deadline: May 1, 2018

Investigator Studies Program—Hepatitis A, Hepatitis B

http://engagezone.msd.com/other.php

Effective December 2017, the Investigator Studies Program (MISP) Committee will accept proposals within our current areas of interest (AOI) up to May 1, 2018.

The following areas are of interest to Investigator Studies Program Committee:

Studies evaluating the epidemiology and health economic burden of hepatitis A in regions, countries or populations in which these data are limited.

Studies evaluating the mechanisms underlying non-response to hepatitis B vaccination, as well as strategies to overcome non-response.

Studies that assess novel methods for improving series completion in high risk populations.

Full Protocol Submission with Detailed Budget: May 1, 2018